Drug Information

Drug General Information
Drug ID
D0J1VY
Former ID
DAP000608
Drug Name
Entacapone
Synonyms
Comtan; Comtess; Entacapona; Entacaponum; Novartis brand of entacapone; Orion brand of entacapone; KB475572; OR 611; COM-998; Comtan (TN); Entacapona [INN-Spanish]; Entacapone [USAN:INN]; Entacaponum [INN-Latin]; OR-611; Stalevo (TN); Entacapone (JAN/USAN/INN); N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
Drug Type
Small molecular drug
Indication Parkinson's disease [ICD9: 332; ICD10:G20] Approved [536923], [541757]
Therapeutic Class
Antiparkinson Agents
Company
Norvatis Phamaceuticals Corporation
Structure
Download
2D MOL

3D MOL
Formula
C14H15N3O5
InChI
InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
InChIKey
JRURYQJSLYLRLN-BJMVGYQFSA-N
CAS Number
CAS 130929-57-6
PubChem Compound ID
5281081
PubChem Substance ID
10145, 7847846, 7979169, 8616509, 11528716, 12014660, 14776335, 26757974, 39290001, 46508734, 49658624, 50064207, 50214283, 53790856, 57358005, 92308972, 92719407, 93166184, 103248957, 104004044, 113854525, 119504915, 121682934, 124893160, 126530712, 126592033, 126620827, 126653084, 126666453, 131297374, 134337899, 135017133, 135032923, 137001453, 141610450, 144115941, 144205737, 152104428, 160963840, 163620784, 163686109, 164814929, 164840953, 170464850, 172917348, 175268297, 175610943, 176484081, 177748942, 178103260
ChEBI ID
ChEBI:4798
SuperDrug ATC ID
N04BX02
SuperDrug CAS ID
cas=116314671
Target and Pathway
Target(s) Catechol-O-methyl-transferase Target Info Inhibitor [535173], [535204]
BioCyc Pathway L-dopa degradation
Dopamine degradation
Noradrenaline and adrenaline degradation
KEGG Pathway Steroid hormone biosynthesis
Tyrosine metabolism
Metabolic pathways
Dopaminergic synapse
PANTHER Pathway Adrenaline and noradrenaline biosynthesis
Dopamine receptor mediated signaling pathway
PathWhiz Pathway Tyrosine Metabolism
WikiPathways Methylation Pathways
Metapathway biotransformation
Estrogen metabolism
Biogenic Amine Synthesis
Dopamine metabolism
Phase II conjugation
Neurotransmitter Clearance In The Synaptic Cleft
References
Ref 536923Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
Ref 541757(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6647).
Ref 535173Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
Ref 535204Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.